Combination Chemotherapy with CDDP and 5-FU in Head and Neck Cancer

Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck

“…The rationale for administering 5-FU on days 1 to 2 1 0 0 3 6 Febrile neutropenia 0 0 1 0 0 1 Neutropenia 3 1 1 3 4 a 12 Anorexia 1 0 0 1 0 2 Lymphocytopenia 2 0 0 1 0 3 Elevated creatinine 5 followed by administration of cisplatin on day 4 was based on previous preclinical and clinical data showing better efficacy in SCCHN when this administration sequence was used, rather than cisplatin followed by 5-FU. [14][15][16][17][18] The MTD was identified as docetaxel 70 mg/m 2 , cisplatin 70 mg/m 2 , and 5-FU 750 mg/m 2 per day. The regimen was generally well tolerated and resulted in a high overall response rate, of 94% (17 PRs/18 patients) and a CR rate of 22% in the primary site (4/18 patients).…”

“…The rationale for administering 5-FU on day 1 and cisplatin on day 4 was based on previous preclinical and clinical data showing better efficacy in SCCHN when this administration sequence was used, rather than cisplatin followed by 5-FU. [14][15][16][17][18] Patients received antiemetic therapy with intravenous dexamethasone (8 mg) and a 5-hydroxytryptamine (HT3) receptor antagonist immediately prior to the cisplatin infusion on day 4 and on days 5 through 8. At least three patients were to be enrolled at each dose level.…”

Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer

“…In the present study, we confirmed that squamous cell carcinoma was highly sensitive to docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU) using the histoculture drug response assay [2][3][4]. Moreover, improvements reported in the response rates and survival rates in previous studies with CDDP and 5-FU chemotherapy have not been satisfactory [5][6][7]. For this reason we have previously conducted a feasibility study, with the dosages of these agents based upon findings from a phase I study [8].…”

“…The CR rate and the 5-year survival rate were 12.3% and 48.5%, respectively, after treatment using a protocol that involved the infusion of CDDP (50 mg/m 2 ) on day 1, followed by the administration of 5-FU (750 mg/m 2 ) by intravenous systemic infusion for 120 h from days 2 to 6 [5][6][7]13]. The CR rate and the 5-year survival rate were 47.6% and 64.0%, respectively, after treatment that entailed the infusion of CDDP (100 mg/m 2 ) by SIC on day 1, followed by the intravenous administration of 5-FU (750 mg/m 2 ) for 120 h from days 2 to 6 [2][3][4].…”